Matrix Metalloproteinases and Cardiovascular Disease
- 1 November 1995
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 77 (5), 863-868
- https://doi.org/10.1161/01.res.77.5.863
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis.Heart, 1995
- Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?Arthritis & Rheumatism, 1994
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.JCI Insight, 1994
- Physiological consequences of loss of plasminogen activator gene function in miceNature, 1994
- Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle-derived cell lineJournal of Cellular Physiology, 1993
- Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.Heart, 1993
- Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factorAtherosclerosis, 1991
- Tissue inhibitor of metalloproteases (TIMP) is matrix associated in aortic tissue: Report of a radioimmunoassayBiochemical and Biophysical Research Communications, 1990
- INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUESThe Lancet, 1989
- Immune mechanisms in atherosclerosis.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989